It is difficult to know to what extent performance-based EREs have been successful to date. Few countries have formally assessed their experience. The confidentiality of agreements remains an obstacle to independent evaluation and little public evidence is availab evidence. However, information from expert interviews and previous studies shows that reports on the Evidence Development (EDC) agreements have so far had a poor record in reducing uncertainty about drug performance. Default payment agreements (PbRs) are still widespread, but they do not always provide evidence of product performance because the data used to trigger payments is not always aggregated and analyzed. The administrative burden of collecting and analyzing drug performance data can also make execution costly. Despite the lack of evidence, experience to date with results-based agreements indicates a number of good practices. These are four main themes: note: This taxonomy is based solely on the structure of the agreements. All types of agreements mentioned above may exist not only between companies and health organizations, but also between companies and other types of institutions that constitute a health system, including government agencies or national authorities responsible for making coverage or pricing decisions and/or evaluating health technologies (HTA), regional health authorities, health care providers, etc. In particular, for products used in hospitals, MEAs may be available between companies and hospitals. Source: authors of the study based on Carlson (2010), Ferrario and Kanavos (2013) and Gerkens et al. (2017). “Explore the experience that countries have gained so far with performance MMAs to determine best practices and best ways to make better use of these agreements in the future.” Read the report here.
Learn more about MEAs (sometimes called access to employment agreements or MANAGED AEDs). Assessing the strengths and weaknesses of managed accession agreements (MEA) in Belgium. The report “Performance-based managed entry agreements for new medicines” highlighted the study`s current limitations, such as absence. B of existing data analytics and the widespread use of confidentiality around agreements. The Organisation for Economic Co-operation and Development (OECD) has published a report on entry arrangements (WMA) which reviews this approach and makes recommendations for improvement. Entry-level managed agreements are agreements between companies and health care recipients that cover new drugs while facing uncertainty about their financial impact or performance. Financial agreements are used in at least two-thirds of OECD and EU member states. Many of these countries also use results-related agreements, which subordinate coverage, business payments or discounts paid by companies to product performance, but these MEAs are less common. With the help of the European Commission, the OECD has reviewed the experience of countries that have adopted performance measures to date to identify best practices and opportunities to use these agreements in the future. Confidentiality of performance-based MEA information versus interest in such informationNumbre from countries where information is not confidential and where there is interest in such information from other countries, based on interviews with experts from 12 OECD countries (1) using PERFORMANCE-based MEAs… Managed membership agreement.- Published: Information is in the public domain (z.B.